PE
CTNM

Point72 Europe’s Contineum Therapeutics CTNM Stock Holding History

Point72 Europe’s Portfolio CTNM Stock Details CTNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$2.1K Buy
+179
New +$1.44K ﹤0.01% 660

Other funds holding CTNM

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

Point72 Europe's CTNM Position: Q3 2025 in Review

Point72 Europe opened a new position in Contineum Therapeutics (CTNM) in Q3 2025: 179 shares worth $2.1K. The stake represents ﹤0.01% of the portfolio and ranks #660 among its holdings.

62 funds tracked by Wall St. Rank hold CTNM as of Q3 2025.

  • Point72 Europe held 179 shares of Contineum Therapeutics worth $2.1K as of Q3 2025.
  • Contineum Therapeutics was a new Point72 Europe position in Q3 2025.
  • Contineum Therapeutics made up ﹤0.01% of Point72 Europe's portfolio in Q3 2025, its #660 holding.
  • 62 funds tracked by Wall St. Rank held Contineum Therapeutics as of Q3 2025.

Based on Point72 Europe's 13F filing for Q3 2025, filed 14 Nov 2025.